HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose more than 5% in midday trading. The drug Cristabetin, which is used to treat glaucoma, has been approved for market launch.
Tricorono Eye Clinic-B (06622) rose more than 5% intraday, and as of the time of writing, rose by 3.7% to 1.4 Hong Kong dollars, with a trading volume of 496,500 Hong Kong dollars.
, ZHAOKE OPHTH-B (06622) rose more than 5% during trading hours, and as of the time of writing, it has increased by 3.7% to 1.4 Hong Kong dollars, with a turnover of 496,500 Hong Kong dollars.
On the news front, Zhaoke Ophthalmology announced this morning that its anti-glaucoma drug Bymicrontal prostaglandin eye drops (Crystalbet Clear) developed and produced by the company has been approved for listing by the National Medical Products Administration. It is reported that Bymicrontal prostaglandin eye drops (Crystalbet Clear) is the first single dosage prostaglandin eye drops in China without preservatives, used to reduce eye pressure in patients with angle-closure glaucoma and high eye pressure.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
